| Objective: The purpose of this project is to objectively evaluate the effect of Xuefu Zhuyu Granules on the hypercoagulability status of patients with advanced non-small cell lung cancer.Methods: According to the principle of randomized controlled trials in clinical research,based on the inpatients with advanced non-small cell lung cancer in Weifang Traditional Chinese Medicine Hospital,60 patients were randomly divided into the control and the experimental group according to diagnostic criteria,inclusion criteria,and exclusion criteria.30 patients in the control group were given conventional treatment(standard antitumor chemotherapy regimen combined with low molecular weight heparin),and 30 patients in the test group were treated with Xuefu Zhuyu Decoction on the basis of the control group.21 days is a cycle.Observe 2 cycles.Record the changes of blood coagulation index,malignant tumor venous thromboembolism risk score(Khorana),TCM syndrome score,quality of life score(KPS),and safety evaluation before and after treatment.The data was analyzed and processed in strict accordance with statistical methods using SPSS 26.0.Results: 1.There were no statistics on general information(gender,age,pathological classification,staging),changes in blood coagulation parameters,venous thromboembolism risk score(Khorana),TCM syndrome score,and quality of life score(KPS)before treatment.The differences are all comparable.2.Coagulation indicators:(1)After treatment,the D-dimer value of the test group decreased,which was slightly lower than that of the control group,and there was no significant statistical difference(P=0.062).In the comparison within the group,the D-dimer decreased significantly after treatment in the experimental group,and the D-dimer value decreased slightly after treatment in the control group,all with significant statistical differences(P<0.01).(2)After treatment,the FIB values of both groups decreased,and the test group was lower than the control group,with a significant statistical difference(P <0.01).In the comparison within the group,the test group significantly decreased after treatment,from 5.5743 ± 1.29106 g / d L to3.4617 ± 0.80848 g / d L,there was a significant statistical difference(P<0.01);the control group slightly decreased after treatment,no statistics Difference(P=0.126).(3)After treatment,the APTT in both groups was prolonged within the normal range,and the test group was higher than the control group,with a significant statistical difference(P=0.002).In the comparison between the two groups,there were statistical differences between the two groups(P<0.01).(4)After treatment,the PT in both groups increased within the normal range.The test group was slightly higher than the control group,and there was no significant difference(P=0.552).In the comparison within the group,there were significant statistical differences between the two groups(P<0.01).3.Khorana risk score:After treatment,there were significant differences between the two groups(P<0.01).In the comparison within the group,the total risk value of the experimental group decreased after treatment,and there was a significant statistical difference(P=0.018);the total risk value of the control group increased slightly after treatment,without significant statistical difference(P=0.302).4.TCM syndrome score:The scores of the two groups after treatment were lower than those before treatment,and the test group was significantly lower(P<0.01),with significant statistical differences.In the comparison within the group,the score of the test group was significantly reduced,and there was a significant statistical difference,while the score of the control group was slightly decreased,and there was no statistical difference(P=0.074).The number of significant and effective patients in the experimental group was more than that in the control group,P<0.01.There was a significant statistical difference between the two groups.5.KPS score:After treatment,there were significant differences between the two groups(P<0.01).Within the group,the control group had P=0.074,which was not statistically significant,and the experimental group had a significant statistical difference(P<0.01).The KPS score of the experimental group was improved in 20 cases,and the stability was 6;the KPS score of the control group was improved in 8 cases,and the stable was7 cases.After the rank sum test,there was a statistical difference between the two groups.6.Safety evaluation:In this trial study,after taking Xuefu Zhuyu Decoction,no adverse reactions and toxic side effects directly related to the drug were observed.Conclusion: Xuefu Zhuyu Decoction can effectively improve the hypercoagulable state of patients with advanced non-small cell lung cancer,reduce the risk of venous thromboembolism,or have a synergistic effect on conventional western medicine treatment of non-small cell lung cancer.The clinical symptoms of traditional Chinese medicine improve the quality of life of patients without causing significant adverse reactions,and the safety of medication is high. |
PDF Full Text Request